We recently utilized one of these inhibitors, NSC668394 (NSC), which preferentially binds to and inhibits ezrin activity over other ERMs (8) and showed that it reduced ezrin activity in vitro and attenuated cancer cell migration and lymph node metastasis in vivo (7). The gene discussed is EZR; the disease is cancer.